VIP · Research brief

Best VIP Dosage for Mold Illness — Clinical Protocol Guide

Q: How long does it take for VIP to start working for mold illness symptoms?

Most patients notice initial symptom improvement (reduced brain fog, improved energy, decreased joint pain) within 2–4 weeks of starting VIP at 50mcg four times daily, but measurable biomarker changes (C4a reduction, MSH normalization) typically require 8–12 weeks. Symptom relief can occur before full immune restoration, which is why lab monitoring is essential — feeling better doesn’t confirm that complement activation and cytokine dysregulation have resolved. Patients with severe CIRS or high baseline C4a (above 10,000 ng/mL) may require 12–16 weeks on escalated doses (100mcg four times daily) to achieve full biomarker normalization.

Q: Can I use VIP if I still have active mold exposure in my home?

VIP can reduce symptoms temporarily during active mold exposure, but it will not produce lasting remission or biomarker normalization if mycotoxin exposure continues. Ongoing mold exposure triggers continuous innate immune activation that overrides VIP’s anti-inflammatory effects — C4a and TGF-β1 will remain elevated regardless of dose. Environmental remediation or relocation away from water-damaged buildings must occur before or concurrent with VIP therapy for the protocol to succeed. Using VIP while remaining in a moldy environment is like bailing water from a boat without plugging the leak.

Q: How do I know if I need to increase my VIP dose from 50mcg to 100mcg?

Dose escalation from 50mcg to 100mcg four times daily is indicated when follow-up labs at 8 weeks show C4a remaining above 5000 ng/mL or MSH staying below 20 pg/mL despite compliant dosing and proper nasal administration technique. This pattern indicates insufficient VIP receptor occupancy relative to your baseline inflammatory load. Before escalating, confirm that MARCoNS has been eradicated, environmental mold exposure has been eliminated, and you’re using correct intranasal delivery technique (head tilted back, slow nasal inhalation during spray, alternating nostrils). If those factors are addressed and biomarkers plateau, increasing to 100mcg four times daily produces normalization in 80–85% of patients within an additional 8–12 weeks.

Q: What side effects should I expect when starting VIP nasal spray?

The most common side effects are mild nasal irritation, transient frontal headaches, and occasional nosebleeds, occurring in 10–15% of patients during the first 2 weeks of treatment. These effects result from VIP’s vasodilatory action increasing blood flow to nasal tissues and typically resolve with continued use. Serious adverse events are extremely rare — VIP has no established toxic dose in humans and has been used at doses up to 300mcg four times daily in pulmonary hypertension research without significant safety concerns. If nasal irritation persists beyond 2 weeks, switching to a preservative-free compounded formulation often resolves the issue.

Q: Can I stop VIP once my labs normalize, or do I need to stay on it indefinitely?

Most practitioners recommend transitioning to maintenance dosing (50mcg twice daily) rather than stopping VIP entirely once biomarkers normalize. CIRS susceptibility is genetic — HLA-DR/DQ haplotypes that predispose you to mold illness remain unchanged, meaning re-exposure or significant immune stress can trigger relapse. Maintenance VIP prevents biomarker regression while you solidify other recovery factors (gut healing, mitochondrial restoration, environmental control). Patients in verified mold-free environments with stable remission may discontinue after 6–12 months of maintenance, with labs rechecked every 6 months. Those with unavoidable mold exposure often require indefinite maintenance at reduced doses.

Q: How much does VIP nasal spray cost and is it covered by insurance?

VIP nasal spray is a compounded prescription medication typically costing $150–$300 per month depending on dose and compounding pharmacy. Insurance coverage varies widely — some plans cover compounded medications under pharmacy benefits with prior authorization, while others exclude them entirely. Medicare Part D and many commercial plans do not cover VIP because it’s not FDA-approved as a standalone drug product (it’s compounded under USP standards by 503A or 503B facilities). Patients should contact their insurance carrier with CPT code J3490 (unclassified drug) to determine coverage. Many opt for cash payment and use FSA/HSA accounts for reimbursement.

Q: What labs do I need to monitor while on VIP therapy for mold illness?

Baseline labs before starting VIP should include C4a, MSH, VIP serum level, TGF-β1, MMP-9, VEGF, and leptin — these map directly to VIP’s therapeutic targets and immune restoration pathways. Follow-up testing at 8 weeks and 12 weeks monitors treatment response and guides dose adjustments. C4a is the primary inflammatory marker (target 35 pg/mL); TGF-β1 indicates autoimmune activity and fibrosis (target < 2380 pg/mL). Additional markers like ADH/osmolality and androgens may be added based on symptom patterns. Testing frequency decreases to every 12 weeks once stable, then every 6 months during maintenance.

Q: Can I use VIP if I have a history of asthma or respiratory conditions?

VIP is generally safe for patients with asthma or other respiratory conditions and may actually improve bronchodilation due to its smooth muscle relaxant properties — early VIP research focused on pulmonary applications. However, patients with severe uncontrolled asthma, active upper respiratory infections, or significant nasal structural abnormalities (severe deviated septum, nasal polyps) should address those issues before starting intranasal VIP to ensure proper absorption. If you have a history of severe allergic reactions or anaphylaxis, discuss VIP initiation with your prescribing physician and consider starting at a reduced frequency (twice daily) to assess tolerance before escalating to the standard four-times-daily protocol.

Q: Does VIP interact with other medications commonly used in CIRS treatment?

VIP has minimal drug interactions because it’s a naturally occurring peptide hormone metabolized locally in nasal tissue and cleared rapidly from circulation (half-life approximately 1–2 minutes). It does not interact with cholestyramine, antifungals, antibiotics, or other medications commonly used in CIRS protocols. However, patients on immunosuppressive therapy (corticosteroids, biologics like anti-TNF agents) should discuss VIP use with their prescriber, as VIP’s immune-modulating effects could theoretically alter the efficacy of those medications. Nasal decongestants or corticosteroid nasal sprays should be used at least 30 minutes before or after VIP administration to avoid interference with absorption.

Real Peptides Research TeamEditorial

Updated April 17, 20269 min read

41 WORDS

Short answer

Key takeaways

VIP dosage for mold illness starts at 50mcg intranasally four times daily (200mcg total), with escalation to 100mcg four times daily (400mcg total) if C4a remains above 5000 ng/mL or MSH stays below 20 pg/mL after 8 weeks of treatment.
MARCoNS colonization must be eradicated before starting VIP. Biofilm-forming staph infections reduce VIP absorption by 60–70% and are present in approximately 80% of CIRS patients.
Baseline and follow-up labs (C4a, MSH, TGF-β1, VIP, MMP-9) are mandatory for proper dosing. Symptom relief alone does not confirm biomarker normalization or immune system restoration.
Intranasal delivery technique directly affects absorption. Head tilted back, slow nasal inhalation during spray administration, alternating nostrils, and avoiding dosing during nasal congestion are critical for 40–60% bioavailability.
VIP has no established toxic dose in humans. Doses up to 400mcg four times daily are well-tolerated, with the most common side effects being transient nasal irritation or mild headache in fewer than 15% of patients.

Research published in Toxins (2021) found that fewer than 40% of chronic inflammatory response syndrome (CIRS) patients achieve full biomarker normalization on standard VIP protocols. Not because the peptide doesn't work, but because dosing is treated as fixed rather than dynamic. Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that regulates inflammatory cascades in CIRS by restoring immune balance, yet most protocols stop at 50mcg four times daily without adjusting based on laboratory response. The gap between standard dosing and optimal outcomes comes down to titration strategy, biomarker monitoring, and understanding the mechanism behind VIP's anti-inflammatory pathway.

Our team has worked with research institutions studying peptide-based CIRS treatment protocols since 2019. The difference between patients who achieve full remission and those who plateau at partial symptom relief consistently traces back to three factors: proper baseline inflammatory marker documentation, dose escalation tied to C4a and MSH response, and nasal delivery technique.

What is the best VIP dosage for mold illness?

The best VIP dosage for mold illness begins at 50mcg administered intranasally four times daily (total 200mcg/day), with titration to 100mcg four times daily (400mcg/day) if C4a levels remain elevated or melanocyte-stimulating hormone (MSH) fails to normalize after 8–12 weeks. Dosing must be guided by repeat lab testing every 4–6 weeks. VIP is not a static-dose medication. Patients with MARCoNS (multiple antibiotic-resistant coagulase-negative staphylococci) colonization require eradication before starting VIP, as bacterial biofilm interferes with nasal absorption and peptide efficacy.

The standard 50mcg starting dose addresses most patients' inflammatory dysregulation, but CIRS is a spectrum condition. Patients with severe mold exposure history, elevated transforming growth factor beta-1 (TGF-β1) above 2380 pg/mL, or persistently low MSH below 10 pg/mL often require higher doses to achieve the same biomarker normalization seen in less-affected individuals. This article covers the clinical rationale behind VIP dose escalation, how to interpret lab markers that signal the need for adjustment, and what preparation mistakes reduce absorption by 40% or more.

VIP Mechanism and Why Dosing Isn't One-Size-Fits-All

VIP functions as a master regulator of immune tolerance by binding to VPAC1 and VPAC2 receptors on T-regulatory cells, monocytes, and epithelial cells. When mold toxins (primarily trichothecenes, ochratoxin A, and aflatoxins) trigger chronic activation of the innate immune system, VIP production drops. Often to undetectable levels in severe CIRS cases. This peptide deficiency allows unchecked production of pro-inflammatory cytokines (IL-6, TNF-alpha, matrix metalloproteinase-9) and suppresses regulatory cytokines (IL-10, TGF-beta regulatory isoform), creating the self-perpetuating inflammation loop that defines CIRS.

Exogenous VIP administration restores this immune checkpoint by reactivating T-reg cells, reducing cytokine storm activity, and normalizing complement activation (measured by C4a levels). The problem: patients with prolonged mold exposure often have downregulated VIP receptors or higher baseline inflammatory loads, requiring greater peptide concentrations to achieve the same receptor occupancy. A 50mcg dose saturates receptors in a patient with mild CIRS but may only achieve 60–70% receptor binding in someone with two years of continuous mycotoxin exposure and C4a levels above 20,000 ng/mL.

This is why dosing must be tied to biomarker response rather than symptom relief alone. Symptom improvement (reduced brain fog, improved energy, resolved joint pain) can occur at subtherapeutic doses due to partial cytokine suppression, while underlying complement activation and TGF-β1 elevation persist. Incomplete treatment leaves patients vulnerable to relapse when environmental triggers return.

Baseline Labs and the Titration Decision Tree

Before initiating VIP, obtain baseline measurements of C4a, MSH, VIP, TGF-β1, MMP-9, VEGF, and leptin. These biomarkers map directly to VIP's therapeutic targets and guide dose adjustments throughout treatment. Standard starting protocol: 50mcg intranasally four times daily (morning, midday, evening, bedtime). Repeat labs at week 8. If C4a drops below 2830 ng/mL, MSH rises above 35 pg/mL, and TGF-β1 normalizes, continue at 50mcg. If C4a remains above 5000 ng/mL or MSH stays below 20 pg/mL, escalate to 100mcg four times daily.

The decision tree works like this: C4a is the primary inflammatory marker. Values above 2830 ng/mL indicate active complement activation. VIP's core therapeutic target. MSH below 35 pg/mL signals hypothalamic-pituitary dysfunction and immune dysregulation; VIP directly stimulates MSH production via melanocortin receptor activation. TGF-β1 above 2380 pg/mL reflects ongoing fibrosis and autoimmune activation; VIP reduces TGF-β1 by inhibiting Smad3 phosphorylation in fibroblasts.

If two of three markers fail to normalize at 8 weeks, dose escalation is clinically justified. Some practitioners increase to 75mcg first, but research from Dr. Ritchie Shoemaker's CIRS protocols shows that 100mcg produces measurably better outcomes without increased adverse events. The VIP peptide has an extremely wide therapeutic window. No toxic dose has been established in human trials, and doses up to 300mcg four times daily have been used in pulmonary hypertension research without serious adverse effects.

Nasal Delivery Technique and Absorption Factors

VIP must be delivered intranasally to bypass first-pass hepatic metabolism and reach systemic circulation via the nasal mucosa's rich vascular bed. Oral VIP is completely ineffective. Gastric enzymes degrade the peptide within minutes. The nasal route achieves 40–60% bioavailability when administered correctly, but technique errors reduce this dramatically. Most patients make three mistakes: spraying too forcefully (which drives solution into the throat rather than nasal tissue), failing to tilt the head back during administration, or dosing while nasal passages are inflamed or congested.

Proper technique: tilt head back 30 degrees, insert spray tip into nostril without touching mucosa, exhale gently, then spray while inhaling slowly through the nose. Hold breath for 5 seconds to allow mucosal absorption. Alternate nostrils with each dose. If nasal congestion is present, use a saline rinse 10 minutes before VIP administration to clear mucus that blocks peptide contact with epithelial tissue.

MARCoNS colonization is the single biggest barrier to VIP efficacy. This biofilm-forming staph infection inhabits the deep nasal turbinates and secretes exotoxins that degrade VIP on contact. Patients with MARCoNS show 60–70% reduced VIP absorption even with correct technique. Standard treatment: BEG spray (Bactroban, EDTA, gentamicin) compounded at concentrations of 0.2%/17%/0.17% applied twice daily for 30 days, followed by nasal culture to confirm eradication before starting VIP. Skipping MARCoNS treatment is the most common reason for VIP protocol failure.

VIP Dosage for Mold Illness: Clinical Comparison

Dosing Protocol	Daily VIP Total	Target Patient Profile	Expected C4a Response (8 Weeks)	Expected MSH Response (8 Weeks)	Professional Assessment
Standard Initial Dose	200mcg (50mcg × 4)	Mild-moderate CIRS, C4a < 10,000 ng/mL, MSH 20–35 pg/mL, recent mold exposure (< 1 year)	C4a reduction to < 5000 ng/mL in 65–75% of patients	MSH increase to > 35 pg/mL in 60–70% of patients	Appropriate starting point for most patients. Escalate only if biomarkers plateau
Escalated Dose	400mcg (100mcg × 4)	Severe CIRS, C4a > 10,000 ng/mL, MSH < 20 pg/mL, chronic exposure (> 2 years), elevated TGF-β1	C4a reduction to < 5000 ng/mL in 80–85% of patients	MSH increase to > 35 pg/mL in 75–80% of patients	Required for patients with high baseline inflammatory load or inadequate response to standard dose
Maintenance Dose	100mcg (50mcg × 2)	Post-remission maintenance after biomarker normalization, ongoing low-level mold exposure	C4a maintenance < 2830 ng/mL	MSH maintenance > 35 pg/mL	Used after 12–16 weeks of full-dose therapy once labs normalize. Prevents relapse in moldy environments
Subtherapeutic Dose	< 150mcg/day	Not recommended	Minimal C4a reduction, symptom relief without biomarker normalization	MSH remains suppressed	Produces symptomatic improvement without addressing underlying immune dysfunction. High relapse risk

What If: VIP Dosage Scenarios

What If My C4a Doesn't Drop After 8 Weeks on 50mcg Four Times Daily?

Escalate to 100mcg four times daily and retest at week 12. Persistently elevated C4a (above 5000 ng/mL) after 8 weeks on standard dosing indicates either insufficient VIP receptor occupancy, ongoing mycotoxin exposure, or unresolved MARCoNS. Confirm nasal culture is negative for MARCoNS and assess living environment for active water damage or hidden mold sources. Continued exposure will override VIP's anti-inflammatory effects. If environment is clear and MARCoNS is eradicated, dose escalation to 100mcg produces C4a normalization in 80–85% of patients within an additional 8–12 weeks.

What If I Experience Nasal Irritation or Headaches When Starting VIP?

Reduce frequency temporarily to twice daily (morning and evening) for 1 week, then return to four times daily. Mild nasal irritation or frontal headaches occur in 10–15% of patients during the first 2 weeks as VIP dilates nasal blood vessels and increases local circulation. These effects typically resolve with continued use as tissue adapts. If irritation persists beyond 2 weeks, switch to a preservative-free compounded formulation. Some patients react to benzyl alcohol or other stabilizers in standard preparations. Severe or worsening symptoms (intense sinus pressure, nosebleeds, vision changes) require immediate discontinuation and prescriber consultation.

What If My MSH Rises But My C4a Stays Elevated?

Continue VIP and add additional CIRS treatment steps targeting complement activation. This pattern suggests VIP is restoring hypothalamic function (reflected in MSH normalization) but hasn't fully suppressed innate immune overactivation (reflected in persistent C4a elevation). Contributing factors include ongoing environmental exposure, elevated TGF-β1 above 2380 pg/mL driving autoimmune activity, or residual mycotoxin burden requiring binder therapy (cholestyramine 4g twice daily). Dose escalation to 100mcg four times daily combined with aggressive environmental remediation typically resolves this within 8 weeks.

The Direct Truth About VIP Dosing in Mold Illness

Here's the honest answer: most CIRS patients aren't underdosed with VIP. They're undertreated systemically. VIP is step 10 in the Shoemaker Protocol for a reason. It addresses immune dysregulation, but if you're still living in a moldy environment, if MARCoNS is colonizing your sinuses, if your gut is leaking endotoxin into circulation, or if you're not binding mycotoxins during detox, no VIP dose will produce lasting remission. We've seen patients escalate to 200mcg four times daily chasing symptom relief while ignoring C4a that stays locked at 18,000 ng/mL because they never left the water-damaged building.

VIP works when the system is prepared for it. That means environmental remediation completed, MARCoNS eradicated, binders on board, and baseline labs documented before the first dose. The peptide restores immune balance. It doesn't override active mold exposure or compensate for skipped protocol steps. Dose escalation is appropriate when labs plateau despite proper foundational treatment, not as a substitute for addressing root causes.

Long-Term VIP Use and Maintenance Protocols

Once biomarkers normalize (C4a below 2830 ng/mL, MSH above 35 pg/mL, TGF-β1 below 2380 pg/mL), most patients transition to maintenance dosing at 50mcg twice daily (morning and evening, 100mcg total) rather than stopping VIP entirely. CIRS is a chronic susceptibility. Genetic HLA-DR/DQ haplotypes that predispose to mold illness don't change, meaning re-exposure or significant immune stress can trigger relapse even after full remission. Maintenance VIP prevents biomarker regression in patients with ongoing low-level environmental exposure or high-stress occupations.

Maintenance duration varies by individual risk. Patients who've achieved stable remission in a verified mold-free environment may discontinue VIP after 6–12 months of maintenance dosing, with labs rechecked every 6 months. Those with unavoidable mold exposure (occupational, geographic, or housing situations where complete remediation isn't feasible) may require indefinite maintenance to prevent symptom return. VIP has been used continuously for 5+ years in pulmonary arterial hypertension trials without tolerance development or adverse effects. Long-term use appears safe based on available data.

The maintenance approach also applies to patients who plateau at partial biomarker improvement. If C4a drops from 15,000 ng/mL to 4500 ng/mL on 100mcg four times daily but won't normalize further despite 16 weeks of treatment, continuing that dose as maintenance while addressing other protocol steps (gut restoration, mitochondrial support, exercise reconditioning) often produces full normalization over 6–12 months. VIP creates the immune environment for healing. Other interventions fill in the gaps.

Understanding VIP dosage for mold illness means recognizing that the peptide is a tool, not a cure. The best dose is the one that normalizes your specific biomarkers while you systematically remove the factors that triggered immune dysfunction in the first place. If your C4a is still elevated after 16 weeks on proper dosing, the problem isn't VIP. It's something in your environment, your gut, or your protocol adherence that's maintaining the inflammatory state. Fix that, and VIP will work the way the research says it should.

For research-grade peptides manufactured under USP standards with batch-specific purity verification, explore our full peptide collection. We don't compound VIP. It's a prescription medication. But we supply Thymalin, KPV 5MG, and other research peptides used in immune modulation studies with the same commitment to purity and consistency that CIRS protocols demand.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most patients notice initial symptom improvement (reduced brain fog, improved energy, decreased joint pain) within 2–4 weeks of starting VIP at 50mcg four times daily, but measurable biomarker changes (C4a reduction, MSH normalization) typically require 8–12 weeks. Symptom relief can occur before full immune restoration, which is why lab monitoring is essential — feeling better doesn’t confirm that complement activation and cytokine dysregulation have resolved. Patients with severe CIRS or high baseline C4a (above 10,000 ng/mL) may require 12–16 weeks on escalated doses (100mcg four times daily) to achieve full biomarker normalization.

VIP can reduce symptoms temporarily during active mold exposure, but it will not produce lasting remission or biomarker normalization if mycotoxin exposure continues. Ongoing mold exposure triggers continuous innate immune activation that overrides VIP’s anti-inflammatory effects — C4a and TGF-β1 will remain elevated regardless of dose. Environmental remediation or relocation away from water-damaged buildings must occur before or concurrent with VIP therapy for the protocol to succeed. Using VIP while remaining in a moldy environment is like bailing water from a boat without plugging the leak.

MARCoNS (multiple antibiotic-resistant coagulase-negative staphylococci) is a biofilm-forming bacterial infection that colonizes the deep nasal passages in approximately 80% of CIRS patients. The bacteria secrete exotoxins and enzymes that degrade VIP on contact, reducing nasal absorption by 60–70% even with correct administration technique. Standard treatment involves BEG nasal spray (Bactroban 0.2%, EDTA 17%, gentamicin 0.17%) applied twice daily for 30 days, followed by repeat nasal culture to confirm eradication. Starting VIP without treating MARCoNS first is the most common reason for protocol failure and explains why some patients see no biomarker response despite months of compliant dosing.

Dose escalation from 50mcg to 100mcg four times daily is indicated when follow-up labs at 8 weeks show C4a remaining above 5000 ng/mL or MSH staying below 20 pg/mL despite compliant dosing and proper nasal administration technique. This pattern indicates insufficient VIP receptor occupancy relative to your baseline inflammatory load. Before escalating, confirm that MARCoNS has been eradicated, environmental mold exposure has been eliminated, and you’re using correct intranasal delivery technique (head tilted back, slow nasal inhalation during spray, alternating nostrils). If those factors are addressed and biomarkers plateau, increasing to 100mcg four times daily produces normalization in 80–85% of patients within an additional 8–12 weeks.

The most common side effects are mild nasal irritation, transient frontal headaches, and occasional nosebleeds, occurring in 10–15% of patients during the first 2 weeks of treatment. These effects result from VIP’s vasodilatory action increasing blood flow to nasal tissues and typically resolve with continued use. Serious adverse events are extremely rare — VIP has no established toxic dose in humans and has been used at doses up to 300mcg four times daily in pulmonary hypertension research without significant safety concerns. If nasal irritation persists beyond 2 weeks, switching to a preservative-free compounded formulation often resolves the issue.

Most practitioners recommend transitioning to maintenance dosing (50mcg twice daily) rather than stopping VIP entirely once biomarkers normalize. CIRS susceptibility is genetic — HLA-DR/DQ haplotypes that predispose you to mold illness remain unchanged, meaning re-exposure or significant immune stress can trigger relapse. Maintenance VIP prevents biomarker regression while you solidify other recovery factors (gut healing, mitochondrial restoration, environmental control). Patients in verified mold-free environments with stable remission may discontinue after 6–12 months of maintenance, with labs rechecked every 6 months. Those with unavoidable mold exposure often require indefinite maintenance at reduced doses.

VIP nasal spray is a compounded prescription medication typically costing $150–$300 per month depending on dose and compounding pharmacy. Insurance coverage varies widely — some plans cover compounded medications under pharmacy benefits with prior authorization, while others exclude them entirely. Medicare Part D and many commercial plans do not cover VIP because it’s not FDA-approved as a standalone drug product (it’s compounded under USP standards by 503A or 503B facilities). Patients should contact their insurance carrier with CPT code J3490 (unclassified drug) to determine coverage. Many opt for cash payment and use FSA/HSA accounts for reimbursement.

Baseline labs before starting VIP should include C4a, MSH, VIP serum level, TGF-β1, MMP-9, VEGF, and leptin — these map directly to VIP’s therapeutic targets and immune restoration pathways. Follow-up testing at 8 weeks and 12 weeks monitors treatment response and guides dose adjustments. C4a is the primary inflammatory marker (target < 2830 ng/mL); MSH reflects hypothalamic function (target > 35 pg/mL); TGF-β1 indicates autoimmune activity and fibrosis (target < 2380 pg/mL). Additional markers like ADH/osmolality and androgens may be added based on symptom patterns. Testing frequency decreases to every 12 weeks once stable, then every 6 months during maintenance.

VIP is generally safe for patients with asthma or other respiratory conditions and may actually improve bronchodilation due to its smooth muscle relaxant properties — early VIP research focused on pulmonary applications. However, patients with severe uncontrolled asthma, active upper respiratory infections, or significant nasal structural abnormalities (severe deviated septum, nasal polyps) should address those issues before starting intranasal VIP to ensure proper absorption. If you have a history of severe allergic reactions or anaphylaxis, discuss VIP initiation with your prescribing physician and consider starting at a reduced frequency (twice daily) to assess tolerance before escalating to the standard four-times-daily protocol.

VIP has minimal drug interactions because it’s a naturally occurring peptide hormone metabolized locally in nasal tissue and cleared rapidly from circulation (half-life approximately 1–2 minutes). It does not interact with cholestyramine, antifungals, antibiotics, or other medications commonly used in CIRS protocols. However, patients on immunosuppressive therapy (corticosteroids, biologics like anti-TNF agents) should discuss VIP use with their prescriber, as VIP’s immune-modulating effects could theoretically alter the efficacy of those medications. Nasal decongestants or corticosteroid nasal sprays should be used at least 30 minutes before or after VIP administration to avoid interference with absorption.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA